◎ Sugi Atlas

Atlas / Drug / Rifampin

Rifampin

drug
On this page

Also known as AbrifamBA 41166/EBA 411661EBA-41166/EBA-41166EEremfatL-5103L-5103 LEPETITNIH-10782NSC-113926RifaRifadinRifadineRifaldazineRifaldinRifampicinRifampicinaRifampicineRifampicinum

Summary

Rifampin (CHEMBL374478) is an approved small-molecule EC 2.7.7.6 (RNA polymerase) inhibitor (ATC J04AB02) targeting SLCO1A2, SLCO1B1, and SLCO1B3; indicated across 56 conditions including pulmonary tuberculosis and tuberculosis.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: J04AB02
  • Targets: 4 (SLCO1A2, SLCO1B1, SLCO1B3…)
  • Indications: 56 conditions
  • Clinical trials: 367
  • Chemistry: 822.9 Da · C43H58N4O12

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL374478
NameRifampin
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID135398735
ChEBICHEBI:28077
ATCJ04AB02
Molecular formulaC43H58N4O12
Molecular weight822.9
InChIKeyJQXXHWHPUNPDRT-WLSIYKJHSA-N

SMILES: C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C

IUPAC name: [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate

ChEBI definition: A member of the class of rifamycins that is a a semisynthetic antibiotic derived from Amycolatopsis rifamycinica (previously known as Amycolatopsis mediterranei and Streptomyces mediterranei).

Pharmacological roles (ChEBI): EC 2.7.7.6 (RNA polymerase) inhibitor, DNA synthesis inhibitor, antitubercular agent, leprostatic drug, protein synthesis inhibitor, neuroprotective agent, angiogenesis inhibitor, pregnane X receptor agonist, antineoplastic agent, antiamoebic agent, geroprotector.

Other ChEBI roles (chemical / environmental): Escherichia coli metabolite.

Also known as: Abrifam, BA 41166/E, BA 411661E, BA-41166/E, BA-41166E, Eremfat, L-5103, L-5103 LEPETIT, NIH-10782, NSC-113926, Rifa, Rifadin

Patent coverage: 31,040 distinct patent families (93,834 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 92,670 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
SLCO1A2OATP1A2Inhibition4.290.2%P46721
SLCO1B1OATP1B1Inhibition5.960%Q9Y6L6
SLCO1B3OATP1B3Inhibition5.80%Q9NPD5
NR1I2Pregnane X receptorAgonist60.3%O75469

Broader ChEMBL bioactivity targets: 63 (assay-derived). Sample: Microtubule-associated protein tau, Solute carrier organic anion transporter family member 1B1, Solute carrier organic anion transporter family member 1B3, Solute carrier organic anion transporter family member 1A2, Solute carrier organic anion transporter family member 2B1, ATP-binding cassette sub-family C member 4, Solute carrier organic anion transporter family member 1A1, Solute carrier organic anion transporter family member 1A4, Vasopressin V2 receptor, Enoyl-[acyl-carrier-protein] reductase [NADH].

Bioactivity

ChEMBL activities: 40 potent at pChembl ≥ 5 of 94 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
P9WGR17.52IC5030nMCHEMBL_ACT_15041284
NR1I26.72EC50190nMCHEMBL_ACT_16636988
NR1I26.7EC50200nMCHEMBL_ACT_15448139
NR1I26.65EC50226nMCHEMBL_ACT_17979140
SLCO1B16.52IC50300nMCHEMBL_ACT_15448330
NR1I26.25EC50564nMCHEMBL_ACT_29256827
P008116.15Potency707.9nMCHEMBL_ACT_4689205
NR1I26EC501000nMCHEMBL_ACT_26335897
SLCO1B15.96Ki1100nMCHEMBL_ACT_12088879
NR1I25.96EC501100nMCHEMBL_ACT_16516710
NR1I25.93EC501170nMCHEMBL_ACT_25021795
SLCO1B15.92IC501200nMCHEMBL_ACT_12088880
NR1I25.92EC501190nMCHEMBL_ACT_25049966
CYP2B65.89EC501300nMCHEMBL_ACT_15457873
O359135.85Ki1400nMCHEMBL_ACT_11002329
SLCO1B35.85Ki1400nMCHEMBL_ACT_12088877
NR1I25.85EC501400nMCHEMBL_ACT_23266659
O359135.84Ki1460nMCHEMBL_ACT_11002325
NR1I25.84EC501440nMCHEMBL_ACT_25691869
SLCO1B35.82IC501500nMCHEMBL_ACT_12088878
NR1I25.7EC502000nMCHEMBL_ACT_18674058
SLCO1B15.66IC502200nMCHEMBL_ACT_15448320
NR1I25.64EC502300nMCHEMBL_ACT_10936319
SLCO1B15.64IC502300nMCHEMBL_ACT_15448336
ADRA1A5.63AC502332nMCHEMBL_ACT_25137969
P125305.53IC502949nMCHEMBL_ACT_7819675
NR1I25.5EC503200nMCHEMBL_ACT_15463730
NR1I25.46EC503500nMCHEMBL_ACT_15463723
SLCO1B35.3Ki5000nMCHEMBL_ACT_11003207
HTR3A5.28AC505200nMCHEMBL_ACT_25149181

Target pathways

Aggregated over 4 target gene(s): SLCO1A2, SLCO1B1, SLCO1B3, NR1I2.

Top Reactome pathways

21 total, by targets touching each:

PathwayTargetsGenes
Metabolism3SLCO1A2, SLCO1B1, SLCO1B3
Recycling of bile acids and salts3SLCO1A2, SLCO1B1, SLCO1B3
Bile acid and bile salt metabolism3SLCO1A2, SLCO1B1, SLCO1B3
Transport of small molecules3SLCO1A2, SLCO1B1, SLCO1B3
Transport of vitamins, nucleosides, and related molecules3SLCO1A2, SLCO1B1, SLCO1B3
SLC-mediated transmembrane transport3SLCO1A2, SLCO1B1, SLCO1B3
Metabolism of lipids3SLCO1A2, SLCO1B1, SLCO1B3
Organic anion transport by SLCO transporters3SLCO1A2, SLCO1B1, SLCO1B3
Metabolism of steroids3SLCO1A2, SLCO1B1, SLCO1B3
Drug ADME3SLCO1A2, SLCO1B1, SLCO1B3
Disease2SLCO1B1, SLCO1B3
Metabolism of porphyrins2SLCO1B1, SLCO1B3
Heme degradation2SLCO1B1, SLCO1B3
SLC transporter disorders2SLCO1B1, SLCO1B3
Disorders of transmembrane transporters2SLCO1B1, SLCO1B3
Atorvastatin ADME2SLCO1B1, SLCO1B3
Nuclear Receptor transcription pathway1NR1I2
SUMOylation of intracellular receptors1NR1I2
Defective SLCO1B3 causes hyperbilirubinemia, Rotor type (HBLRR)1SLCO1B3
Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR)1SLCO1B1
Ciprofloxacin ADME1SLCO1A2

Dominant GO biological processes

GO termTargets
xenobiotic metabolic process4
monoatomic ion transport3
obsolete organic anion transport3
bile acid and bile salt transport3
sodium-independent organic anion transport3
lipid transport3
transmembrane transport3
heme catabolic process2
obsolete organic cation transport1
prostaglandin transport1
thyroid hormone transport1
negative regulation of transcription by RNA polymerase II1
regulation of DNA-templated transcription1
signal transduction1
steroid metabolic process1

Indications & clinical

Indications

56 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
pulmonary tuberculosis4MONDO:0006052EFO:1000049
tuberculosis4MONDO:0018076MONDO:0018076
multiple system atrophy3MONDO:0007803EFO:1001050
reactive arthritis3MONDO:0017376EFO:0007460
leprosy3MONDO:0005124EFO:0001054
endocarditis3MONDO:0005025MONDO:0000565
Clostridium difficile colitis3MONDO:0000705EFO:1001314
diarrheal disease3MONDO:0001673HP:0002014
meningitis3MONDO:0021108MONDO:0021108
Alzheimer disease3MONDO:0004975MONDO:0004975
AIDS2MONDO:0012268EFO:0000765
Mycobacterium avium complex disease2MONDO:0005866EFO:0007386
onchocerciasis2MONDO:0017137EFO:0007402
Buruli ulcer disease2MONDO:0000327MONDO:0000327
multiple sclerosis2MONDO:0005301MONDO:0005301
cystic fibrosis2MONDO:0009061MONDO:0009061
sarcoidosis2MONDO:0019338MONDO:0019338
melanoma1MONDO:0005105EFO:0000756
non-small cell lung carcinoma1MONDO:0005233EFO:0003060
neoplasm1MONDO:0005070EFO:0000616
constipation disorder1MONDO:0002203HP:0002019
lymphoma1MONDO:0005062EFO:0000574
B-cell chronic lymphocytic leukemia1MONDO:0004948EFO:0000095
Hodgkins lymphoma1MONDO:0004952EFO:0000183
diabetes mellitus1MONDO:0005015EFO:0000400
rheumatoid arthritis1MONDO:0008383EFO:0000685
HIV infectious disease1MONDO:0005109EFO:0000764
endometriosis1MONDO:0005133EFO:0001065
pulmonary arterial hypertension1MONDO:0015924EFO:0001361
metastatic melanoma1MONDO:0005191EFO:0002617
non-Hodgkin lymphoma1MONDO:0018908EFO:0005952
rhinoscleroma1MONDO:0005945EFO:0007470
metabolic dysfunction-associated steatohepatitis1MONDO:0007027EFO:1001249
respiratory syncytial virus infectious disease1MONDO:0001577EFO:1001413
chronic hepatitis B virus infection1MONDO:0005366EFO:0004239
kidney failure1MONDO:0001106HP:0000083
thrombotic disease1MONDO:0000831MONDO:0000831
fungal infectious disease1MONDO:0002041MONDO:0002041
coronary artery disorder1MONDO:0005010EFO:0001645
chronic kidney disease1MONDO:0005300EFO:0003884
essential hypertension1MONDO:0001134MONDO:0001134
type 2 diabetes mellitus1MONDO:0005148MONDO:0005148
Parkinson disease1MONDO:0005180MONDO:0005180
hypercalcemia disease1MONDO:0001566HP:0003072
severe acute respiratory syndrome1MONDO:0005091MONDO:0100096
erectile dysfunction1MONDO:0005362EFO:0004234
anti-neutrophil antibody associated vasculitis1MONDO:0005435EFO:0004826
hematopoietic and lymphoid system neoplasm1MONDO:0002334MONDO:0044881
primary myelofibrosis1MONDO:0009692MONDO:0044903
osteomyelitis0MONDO:0005246EFO:0003102

6 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 367.

Phase distribution

PhaseTrials
PHASE1222
PHASE241
PHASE334
Not specified31
PHASE428
PHASE2/PHASE36
EARLY_PHASE13
PHASE1/PHASE22

Top trials by phase / activity

NCTPhaseStatusTitle
NCT04921943PHASE4RECRUITINGHypertonic Saline for MAC
NCT06172010PHASE4RECRUITINGRifampicin Combination Therapy Versus Monotherapy for Staphylococcal Prosthetic Joint Infection
NCT07084402PHASE4RECRUITINGShort-term Bactericidal Effect of Contezolid in MAC-PD
NCT07330531PHASE4NOT_YET_RECRUITINGDrug-drug Interaction Study of Rifampin and Anaprazole Sodium
NCT00598962PHASE4COMPLETEDUse of Azithromycin and Rifabutin Administered 3 Times Weekly for the Treatment of M. Avium Complex (MAC) Lung Disease
NCT00620438PHASE4UNKNOWNDrug Interaction Between Coartem® and Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients
NCT00711854PHASE4COMPLETEDRandomized Clinical Trial to Compare a Regimen of Trimethoprim-sulfamethoxazole Plus Rifampicin With a Regimen of Linezolid in the Treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection
NCT00985270PHASE4COMPLETEDPregnane X Receptor (PXR) Agonist Rifampicin Effects on Glucose, Lipid and Hormone Homeostasis
NCT01293422PHASE4COMPLETEDEffects of Pregnane X Receptor (PXR) Activation on Human Glucose, Lipid and Hormone Homeostasis
NCT01363765PHASE4COMPLETEDXpert MTB/Rif, a New Tool for the Diagnosis of Pulmonary Tuberculosis in Two Municipalities in Brazil
NCT01380080PHASE4COMPLETEDREMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment
NCT01395654PHASE4UNKNOWNReintroduction Regimens After Hepatitis During Anti-tuberculosis Treatment
NCT01690104PHASE4COMPLETEDThe Effect of PXR Activation on Blood Pressure Regulation
NCT01782950PHASE4UNKNOWNEvaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes
NCT01854489PHASE4COMPLETEDEffects of Rifampicin on the Pharmacokinetics and Pharmacodynamics of Sublingual and Intravenous Buprenorphine
NCT02057796PHASE4COMPLETEDSystematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3
NCT02200978PHASE4COMPLETEDA Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia
NCT02329405PHASE4COMPLETEDThe Effects of PXR Activation on Hepatic Fat Content
NCT02477852PHASE4UNKNOWNThe Optimal Duration of Preoperative Anti-tuberculosis Treatment of Spinal Tuberculosis
NCT02547116PHASE4WITHDRAWNEpidemiology and Treatment of Small-colony Variant Staphylococcus Aureus in Cystic Fibrosis
NCT02576366PHASE4COMPLETEDPhenotypic Drug Probes as Predictors of Drug-drug Interactions With Tacrolimus
NCT02599493PHASE4COMPLETEDEVRIOS : Comparative Evaluation of Low Versus High Doses of Rifampicin
NCT02901288PHASE4UNKNOWNShortened Regimens for Drug-susceptible Pulmonary Tuberculosis
NCT03012529PHASE4COMPLETEDInvestigation of Rifampin to Reduce Pedal Amputations for Osteomyelitis in Diabetics
NCT04006353PHASE4COMPLETEDThe Drug Interaction Between Albuvirtide (ABT) and Rifampin（RIF） in Healthy Adult Subjects
NCT04463680PHASE4COMPLETEDRifampin and the Contraceptive Implant
NCT05021731PHASE4UNKNOWNShort-course Rifamycin-based Regimens for Latent Tuberculosis in Patients With End-stage Kidney Disease
NCT05156437PHASE4TERMINATEDPostoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)
NCT03236987PHASE3RECRUITINGCLArithromycin Versus AZIthromycin in the Treatment of Mycobacterium Avium Complex (MAC) Lung Infections
NCT03474029PHASE2/PHASE3RECRUITINGAssessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
NCT04485156PHASE3NOT_YET_RECRUITINGTreatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3)
NCT04672525PHASE3RECRUITINGRifabutin Versus Rifampicin for Treatment of Staphylococcal PJI Treated With DAIR
NCT04951986PHASE3ACTIVE_NOT_RECRUITINGTesting New Strategies for Patients Hospitalised With HIV-associated Disseminated Tuberculosis
NCT05454345PHASE3NOT_YET_RECRUITINGSitafloxacin-containing Regimens for Shortening Tuberculosis Treatment
NCT05597280PHASE3RECRUITINGBedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy
NCT05766267PHASE2/PHASE3ACTIVE_NOT_RECRUITINGShort-course Regimens for the Treatment of Pulmonary Tuberculosis
NCT05821478PHASE3RECRUITINGEfficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients
NCT05902221PHASE3NOT_YET_RECRUITINGImpact of Rifampicin in Treatment Outcome of Cutibacterium Acnes Prosthetic Joint Infections
NCT05917340PHASE3NOT_YET_RECRUITINGIntensified Short Course Regimen for TBM in Adults
NCT05994742PHASE3ACTIVE_NOT_RECRUITINGAn Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

455 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
RitonavirChEMBL + PubChemPhase 4 (approved)NR1I2, SLCO1A2, SLCO1B1, SLCO1B3
chenodiolPubChemApprovedNR1I2, SLCO1A2, SLCO1B1, SLCO1B3
ErythromycinPubChemApprovedNR1I2, SLCO1A2, SLCO1B1, SLCO1B3
MethotrexatePubChemApprovedNR1I2, SLCO1A2, SLCO1B1, SLCO1B3
AcetaminophenChEMBL + PubChemPhase 4 (approved)NR1I2, SLCO1B1, SLCO1B3
ATAZANAVIRChEMBL + PubChemPhase 4 (approved)NR1I2, SLCO1B1, SLCO1B3
CANDESARTAN CILEXETILChEMBL + PubChemPhase 4 (approved)NR1I2, SLCO1B1, SLCO1B3
CEFOTAXIMEChEMBL + PubChemPhase 4 (approved)NR1I2, SLCO1B1, SLCO1B3
CEFOXITINChEMBL + PubChemPhase 4 (approved)NR1I2, SLCO1B1, SLCO1B3
CEFUROXIMEChEMBL + PubChemPhase 4 (approved)NR1I2, SLCO1B1, SLCO1B3
CEPHAPIRINChEMBL + PubChemPhase 4 (approved)NR1I2, SLCO1B1, SLCO1B3
DigoxinChEMBL + PubChemPhase 4 (approved)SLCO1A2, SLCO1B1, SLCO1B3
HetacillinChEMBL + PubChemPhase 4 (approved)NR1I2, SLCO1B1, SLCO1B3
Hydroxyprogesterone CaproateChEMBL + PubChemPhase 4 (approved)NR1I2, SLCO1B1, SLCO1B3
PravastatinChEMBL + PubChemPhase 4 (approved)SLCO1A2, SLCO1B1, SLCO1B3
RIFAMYCINChEMBL + PubChemPhase 4 (approved)SLCO1A2, SLCO1B1, SLCO1B3
TEGASERODChEMBL + PubChemPhase 4 (approved)NR1I2, SLCO1B1, SLCO1B3
VerapamilChEMBL + PubChemPhase 4 (approved)SLCO1A2, SLCO1B1, SLCO1B3
ATORVASTATINChEMBLPhase 4 (approved)NR1I2, SLCO1B1, SLCO1B3
GlycyrrhizinChEMBL + PubChemPhase 2 (approved)SLCO1A2, SLCO1B1, SLCO1B3
acetylcysteinePubChemApprovedNR1I2, SLCO1B1, SLCO1B3
AlmotriptanPubChemApprovedNR1I2, SLCO1B1, SLCO1B3
DexamethasonePubChemApprovedSLCO1A2, SLCO1B1, SLCO1B3
PyrazinamidePubChemApprovedNR1I2, SLCO1B1, SLCO1B3
dinoprostoneChEMBL + PubChemPhase 4 (approved)NR1I2, SLCO1A2
ERLOTINIBChEMBL + PubChemPhase 4 (approved)SLCO1B1, SLCO1B3
HYDROXYZINE PAMOATEChEMBL + PubChemPhase 4 (approved)SLCO1B1, SLCO1B3
LovastatinChEMBL + PubChemPhase 4 (approved)SLCO1A2, SLCO1B1
OLMESARTAN MEDOXOMILChEMBL + PubChemPhase 4 (approved)SLCO1B1, SLCO1B3
TANNIC ACIDChEMBL + PubChemPhase 4 (approved)SLCO1B1, SLCO1B3
VINBLASTINEChEMBL + PubChemPhase 4 (approved)SLCO1B1, SLCO1B3
BETA CAROTENEChEMBLPhase 4 (approved)SLCO1B1, SLCO1B3
CARBENOXOLONEChEMBLPhase 4 (approved)SLCO1B1, SLCO1B3
CLARITHROMYCINChEMBLPhase 4 (approved)SLCO1B1, SLCO1B3
CYCLOSPORINEChEMBLPhase 4 (approved)SLCO1B1, SLCO1B3
DICLOXACILLINChEMBLPhase 4 (approved)SLCO1B1, SLCO1B3
ELTROMBOPAGChEMBLPhase 4 (approved)SLCO1B1, SLCO1B3
ERYTHROMYCIN ESTOLATEChEMBLPhase 4 (approved)SLCO1B1, SLCO1B3
ERYTHROMYCIN ETHYLSUCCINATEChEMBLPhase 4 (approved)SLCO1B1, SLCO1B3
GEMFIBROZILChEMBLPhase 4 (approved)SLCO1B1, SLCO1B3
INDOMETHACINChEMBLPhase 4 (approved)SLCO1B1, SLCO1B3
LOSARTANChEMBLPhase 4 (approved)SLCO1B1, SLCO1B3
MOMETASONE FUROATEChEMBLPhase 4 (approved)SLCO1B1, SLCO1B3
NONOXYNOL 9ChEMBLPhase 4 (approved)SLCO1B1, SLCO1B3
PACLITAXELChEMBLPhase 4 (approved)SLCO1B1, SLCO1B3
SIMVASTATINChEMBLPhase 4 (approved)NR1I2, SLCO1B1
SIROLIMUSChEMBLPhase 4 (approved)NR1I2, SLCO1B1
SULFASALAZINEChEMBLPhase 4 (approved)SLCO1B1, SLCO1B3
TACROLIMUSChEMBLPhase 4 (approved)NR1I2, SLCO1B1
TELITHROMYCINChEMBLPhase 4 (approved)SLCO1B1, SLCO1B3
TELMISARTANChEMBLPhase 4 (approved)SLCO1B1, SLCO1B3
VINCRISTINEChEMBLPhase 4 (approved)SLCO1B1, SLCO1B3
ADMILPARANTChEMBLPhase 3SLCO1B1, SLCO1B3
ALISPORIVIRChEMBLPhase 3SLCO1B1, SLCO1B3
FASIGLIFAMChEMBLPhase 3SLCO1B1, SLCO1B3
GOSSYPOLChEMBLPhase 3SLCO1B1, SLCO1B3
PAMIPARIBChEMBLPhase 3SLCO1B1, SLCO1B3
SILIBININChEMBLPhase 3SLCO1B1, SLCO1B3
SILYBIN AChEMBLPhase 3SLCO1B1, SLCO1B3
BMS-986020ChEMBLPhase 2SLCO1B1, SLCO1B3

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot